Please assess the completion status of the following clinical trial:

Trial Title: Resiliency Through Azithromycin for Children (REACH), Côte d'Ivoire

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
For expanded azithromycin access during the MDA~Inclusion Criteria:~* Child aged 1 month (at least 30 days) to less than 6 months at the beginning of the week of the MDA intervention~* Resident in study communities~Exclusion Criteria:~* Children below 3.0 kg~* Appears severely ill at the time of the MDA (per the CDD's assessment)~* Unable to swallow liquid delivered through a needle-less syringe because of physical limitations~* Known allergy to macrolides, including azithromycin, based on the primary caregiver's report of prior adverse reaction to medication likely to be a macrolide

- Gender: ALL
- Minimum Age: 1 Month
- Maximum Age: 5 Months
- Healthy Volunteers: t

Study Arms:
- Azithromycin (Type: OTHER): All children ages 1 to 5 months in the targeted health district will be offered a single dose of azithromycin suspension dosed at 20 mg per kg of weight in place of the standard tetracycline ointment, during a mass drug administration targeting trachoma prevention and treatment. All children ages 6 months and older, and all adults already receive the single dose of azithromycin during the MDA event. For this pilot study, single dose of azithromycin is being extended to include the 1 to 5 month old population as well.

Based on this trial design, predict the completion outcome and termination type (if applicable).